Venn Life Sciences Holdings PLC Result of General Meeting (3488V)
20 Juillet 2018 - 4:22PM
UK Regulatory
TIDMVENN
RNS Number : 3488V
Venn Life Sciences Holdings PLC
20 July 2018
Venn Life Sciences Holdings plc
("Venn" or the "Company" or the "Group")
Result of General Meeting
Venn Life Sciences Holdings plc, an Integrated Drug Development
Partner offering a combination of drug development expertise and
clinical trial design and management to pharmaceutical,
biotechnology and medical device clients, is pleased to announce
that at the General Meeting held earlier today, all resolutions
were duly passed.
As a result, the Placing announced on 4 July 2018 of 10,833,335
new ordinary shares at 6 pence per ordinary share (the "Placing
Shares"), is now conditional only on Admission which is expected to
take place on 24 July 2018. An application for the Placing Shares
has been made to London Stock Exchange and the Irish Stock Exchange
for the Placing Shares to be admitted to trading on the AIM market
of the London Stock Exchange and the ESM market of the Irish Stock
Exchange.
The Company also wishes to announce that an application has been
made to the London Stock Exchange and the Irish Stock Exchange for
277,550 new ordinary shares (the "Vendor Shares") of nominal value
GBP0.001 each in the Company to be admitted to trading on the AIM
market of the London Stock Exchange and the ESM market of the Irish
Stock Exchange. The Vendor Shares were issued as consideration for
the acquisition of the 11.03% interest in Venn Life Sciences France
S.A.S as announced on 23 January 2018.
Dealings are expected to commence in both the Placing Shares and
the Vendor Shares (together the "New Ordinary Shares") at 8:00 a.m.
on 24 July 2018.
The New Ordinary Shares will rank in pari passu with the
existing ordinary shares in issue.
Following admission of these New Ordinary Shares, Venn's issued
share capital will consist of 71,395,148 new ordinary shares.
Enquiries:
Venn Life Sciences Holdings plc www.vennlifesciences.com
Allan Wood, Non-Executive Chairman Tel: +44 (0)7785 325 898
Tony Richardson, Chief Executive Officer Tel: +353 1 5499341
Cenkos (Nominated Adviser and Broker) Tel: +44(0)20 7397 8900
Mark Connelly/Steve Cox (Corporate Finance)
Davy (ESM Adviser and Broker) Tel: +353 1 679 6363
Fergal Meegan / Matthew de Vere White
(Corporate Finance)
Hybridan LLP ( Joint Broker) Tel: +44 (0)20 3764 2341
Claire Louise Noyce
About Venn Life Sciences: Venn Life Sciences is an Integrated
Drug Development Partner offering a unique combination of drug
development expertise and clinical trial design and management to
pharmaceutical, biotechnology and medical device organisations.
Venn have dedicated operations in France, Germany, the Netherlands,
the UK, Ireland with partners across Europe and the US.
Further information in relation to Venn Life Sciences is
available on their website - www.vennlifesciences.com
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
ROMSEAFLSFASEFW
(END) Dow Jones Newswires
July 20, 2018 10:22 ET (14:22 GMT)
Hvivo (LSE:HVO)
Graphique Historique de l'Action
De Juin 2024 à Juil 2024
Hvivo (LSE:HVO)
Graphique Historique de l'Action
De Juil 2023 à Juil 2024